You just read:

Debiopharm International SA and Arbor Pharmaceuticals, LLC Announce U.S. FDA Approval for Triptodur™, Triptorelin 6-month Formulation, in the Treatment of Central Precocious Puberty (CPP)

News provided by

Debiopharm International SA

30 Jun, 2017, 13:00 BST